Bavarian Nordic reports promising results for RSV vaccine in phase II trial
On Wednesday morning, Bavarian Nordic announced positive results for the company’s RSV vaccine candidate. According to the biotech company, the candidate has shown an efficacy rate of up to 79 percent in the reduction of symptomatic RSV infections in a phase II trial.
BY CHRISTOFFER DUE KARLSSON, TRANSLATED BY DANIEL INGEMANN KROIER PEDERSEN
The positive news just keeps on coming for Bavarian Nordic.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
.jpg&w=384&q=75)
